E
Edward Swabb
Publications - 14
Citations - 1491
Edward Swabb is an academic researcher. The author has contributed to research in topics: Tarenflurbil & Cognitive decline. The author has an hindex of 9, co-authored 14 publications receiving 1420 citations.
Papers
More filters
Journal ArticleDOI
Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.
Robert C. Green,Lon S. Schneider,David A. Amato,Andrew P. Beelen,Gordon K. Wilcock,Edward Swabb,Kenton Zavitz +6 more
TL;DR: Tarenflurbil did not slow cognitive decline or the loss of activities of daily living in patients with mild AD and had no beneficial effect on the co-primary outcomes.
Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer Disease
Robert C. Green,Lon S. Schneider,David A. Amato,Andrew P. Beelen,Gordon K. Wilcock,Edward Swabb,Kenton Zavitz +6 more
TL;DR: Tarenflurbil had no beneficial effect on the co-primary outcomes (difference in change from baseline to month 18 vs placebo, based on least squares means: 0.1; P =.86 and -0.5 for ADCS-ADL; 95% CI, -1.9 to 0.9;P =.48) using an intent-to-treat analysis as discussed by the authors.
Journal ArticleDOI
Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial
TL;DR: 800 mg tarenflurbil twice per day was well tolerated for up to 24 months of treatment, with evidence of a dose-related effect on measures of daily activities and global function in patients with mild to moderate AD.
Journal ArticleDOI
Safety, Tolerability, Pharmacokinetics, and Aβ Levels After Short-term Administration of R-flurbiprofen in Healthy Elderly Individuals
Douglas Galasko,Neil Graff-Radford,Susanne May,Suzanne Hendrix,Barbara A. Cottrell,Sarah A. Sagi,Gary Mather,Mark Laughlin,Kenton Zavitz,Edward Swabb,Todd E. Golde,Michael P. Murphy,Michael P. Murphy,Edward H. Koo +13 more
TL;DR: R-flurbiprofen had an excellent safety profile and showed dose-dependent central nervous system penetration and showed a short-term effect in plasma that warrants independent verification.
Journal ArticleDOI
Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer
Apostolia Maria Tsimberidou,Wallace Akerley,Matthias C. Schabel,David S. Hong,Cynthia Uehara,Anil Chhabra,Terri Warren,Gary Mather,Brent A. Evans,Deane Woodland,Edward Swabb,Razelle Kurzrock +11 more
TL;DR: In conclusion, MPC-6827 administered intravenously over 2 hours at a dose of 3.3 mg/m2 once weekly for 3 weeks every 28 days was safe in patients with heavily pretreated cancer.